Rein Therapeutics, Inc. (RNTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00887A2042
Rein Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 0.00 USD |
| Operating income | -50.63 m USD |
| EBIT | -50.58 m USD |
| Net income | -49.87 m USD |
| Diluted EPS – continuing operations | -1.96 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Rein Therapeutics, Inc.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium channel, which is in preclinical trial phase for the treatment of cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. The company was incorporated in 2001 and is headquartered in Austin, Texas.
More stocks
- OSE Pharma SA (OSE.PA)
- VirTra, Inc (VTSI)
- NUUO Inc. (6419.TWO)
- Aeon Motor Co Ltd (1599.TWO)
- REGO PAYMENT ARCHITECTURES, INC. (RPMT)
- Werewolf Therapeutics, Inc. (HOWL)
- LumenRadio AB (LUMEN.ST)
- Atlas Lithium Corp (ATLX)
- De Poan Pneumatic (1570.TWO)
- Charlotte's Web Holdings, Inc. (CWBHF)
- EgnsINVEST Ejendomme Tyskland A/S (EGNETY.CO)
- Advagene Biopharma Co. Ltd. (6709.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.